[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prisma Health-Upstate\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,72,94,124,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100637727","effects-of-e-cigarette-flavors-on-adult-e-cigarette-users-with-opioid-use-disorder-100637727",false,"NCT07594717","Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder","Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder Receiving Buprenorphine","FLAVOR","Inclusion Criteria:\n\n* Adults aged 21 years or older.\n* Current e-cigarette users who report e-cigarette use on ≥20 of the past 30 days.\n* Former daily cigarette smokers who currently smoke on ≤19 days per month and no more than 5 cigarettes per day.\n* Diagnosed with opioid use disorder (OUD).\n* Currently receiving buprenorphine treatment for OUD.\n\nExclusion Criteria:\n\n\\-","ALL","21 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal and reinforcing effects of ECs in this population. The goal is to identify EC flavors that may enhance the acceptability of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment.",[25,26],"Nicotine Use Disoder","Opioid Use Disorder","RECRUITING","2026-05-19",{"date":30,"type":31},"2026-05-22","ACTUAL",{"date":33,"type":31},"2025-11-12",{"date":35,"type":21},"2026-05",{"name":37,"class":38},"Prisma Health-Upstate","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":39},"100608475","electronic-cigarettes-as-a-harm-reduction-strategy-among-people-with-opioid-use-disorder-on-buprenorphine-100608475","NCT07202039","Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine","SWITCH","Inclusion Criteria\n\n* Age ≥21 years\n* Smoke ≥5 CPD for ≥1 year\n* Daily CC smoker\n* Willing to switch to EC\n* Exhaled CO ≥6 ppm\n* Diagnosed with OUD\n* Stable on bupropion treatment\n* In good physical and mental health\n* Able to use a smartphone\n* Willing to participate in all study components\n* Able to provide informed consent Exclusion Criteria\n* Interested in quitting CC (contemplation stage of change)\n* Use of EC on ≥4 of the past 30 days\n* Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days\n* Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days\n* Hypertension\n* Medical condition that would contraindicate participation\n* Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode\n* Current suicidal ideation or suicide attempt in the past year\n* Psychiatric hospitalization in the past year\n* Contemplating pregnancy, currently pregnant, or breastfeeding\n* Unable to speak and\u002For read English",{"count":48,"type":21},90,"INTERVENTIONAL",[51],"NA","This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine",[54,55,56],"Tobacco-flavored EC","Sweet-Cooling EC","Sweet Non-cooling EC",[58,59,60,61,62,63],"Cigarette Smoking","Opioid use disorder","Burprenorphine","Electronic cigarettes","Switching","Flavors","2026-05-11",{"date":66,"type":31},"2026-05-12",{"date":68,"type":31},"2026-04-29",{"date":70,"type":21},"2029-06-29",{"name":37,"class":38},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":49,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":39},"100634571","building-retention-and-initiation-through-delivery-of-peer-guided-evidence-based-practices-100634571","NCT07541417","Building Retention and Initiation Through Delivery of Peer-Guided Evidence-Based Practices","Data-Driven Approaches for Opioid Use Disorder Treatment, Recovery, and Overdose Prevention in Rural Communities Via Mobile Health Clinics and Peer Support Services","BRIDGE-SC","Inclusion Criteria:\n\n* Age 18+\n* Have diagnosis of OUD\n* New mobile health MOUD patient\n\nExclusion Criteria:\n\n* Unable to read and comprehend the consent materials and other study materials\n* Currently working with a Certified Peer Support Specialist\n* Having severe medical or psychiatric disability that would hinder participation in the study, as determined by the clinical provider","18 Years",{"count":82,"type":21},750,[51],"This study will provide longitudinal data for 6-months on a target sample of patients with Opioid Use Disorder (OUD) recruited from Prisma Health Mobile Health Clinics in South Carolina. The goal of our study is to increase OUD treatment initiation and retention and maximize prevention of overdose deaths in underserved communities through development, testing, and delivery of a novel intervention targeting areas of optimal allocation of MHC with a Peer Support Specialist (PSS) intervention.",[26],"2026-04-23",{"date":88,"type":31},"2026-04-28",{"date":90,"type":31},"2026-04-08",{"date":92,"type":21},"2029-08-31",{"name":37,"class":38},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":49,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":39},"100600727","phase-4-preoperative-acetazolamide-100600727","NCT07101250","Preoperative Acetazolamide","Preoperative Acetazolamide for Improved Pain Control Following Laparoscopic Hysterectomy","Inclusion Criteria:\n\n* Women\n* Ages 21-65\n* undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without bilateral salpingoophorectomy\n* undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without cystoscopy\n\nExclusion Criteria:\n\n* Allergy to acetazolamide or sulfonamides\n* Known electrolyte disturbances\n* Pregnancy\n* Kidney failure or creatinine \\>1.5\n* Diuretic or lithium use\n* Chronic obstructive pulmonary disease (COPD) or other lung disease\n* Central nervous system disorders\n* Liver disease\n* Glaucoma\n* Preoperative or chronic opioid use\n* Diagnosis of fibromyalgia\n* Preoperative shoulder pain\n* Conversion to laparotomy\n* Intraoperative bladder or bowel injury\n* Inability to understand or utilize visual analog scale\n* Undergoing concurrent reconstructive procedures","FEMALE","65 Years",{"count":104,"type":21},100,[106],"PHASE4","The goal of this randomized study looks at whether giving patients a medicine called acetazolamide (also called Diamox) before they have laparoscopic hysterectomy may decrease postoperative pain. Researchers will compare acetazolamide to a placebo or inactive drug, to see if acetazolamide helps the pain that may occur after surgery from the gas used in the abdomen during the laparoscopic procedure. Patients will be asked to rate their pain before surgery and after surgery through 24 hours.",[109,110,111],"Post Operative Pain","Laparoscopic Hysterectomy","Referred Pain",[113,114,115],"shoulder pain","laparoscopic","analgesia","2026-02-18",{"date":118,"type":31},"2026-02-20",{"date":120,"type":31},"2025-10-30",{"date":122,"type":21},"2026-11-01",{"name":37,"class":38},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":39},"100435199","prevent-cancer--greenville-100435199","NCT04947098","Prevent Cancer- Greenville","Prevent Cancer-Greenville: A Center for Cancer Prevention and Wellness Research Project","CCPW","Inclusion Criteria:\n\n* 18 years or older",true,{"count":134,"type":21},1000,"Prevent Cancer-Greenville was created to provide individuals with the opportunity to have their risk of developing cancer studied. Some individuals may be at a higher risk due to their personal lifestyle, family history and\u002For exposures. If subjects are found to be at high risk for developing a disease, they will be sent to a healthcare provider for further care.",[137,138],"Cancer","High-Risk Cancer","2026-02-11",{"date":141,"type":31},"2026-02-17",{"date":143,"type":31},"2018-11-08",{"date":145,"type":21},"2029-11-08",{"name":37,"class":38},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":101,"minAge":80,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":49,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":39},"100600832","phase-4-intracervical-vasopressin-100600832","NCT07102615","Intracervical Vasopressin","Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception","Inclusion Criteria:\n\n* Women\n* Aged 18-51\n* Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Active hemorrhage- soaking pad\u002Fhour\n* Allergy to vasopressin\n* Concern for intrauterine arteriovenous malformation\n* Inability to consent","51 Years",{"count":156,"type":21},50,[106],"This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.\n\nThe main goal of the study is :\n\n• To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC.\n\nParticipants will:\n\n• would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.",[160],"Retained Products of Conception",[162,163,164],"retained products of conception","intracervical","hysteroscopy","2025-10-31",{"date":167,"type":31},"2025-11-04",{"date":120,"type":31},{"date":170,"type":21},"2026-12-01",{"name":37,"class":38},""]